Surveillance for the use of mycophenolate mofetil for adult patients with lupus nephritis in Japan
- 30 April 2015
- journal article
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 25 (6) , 854-857
Abstract
Mycophenolate mofetil (MMF) is used as one of the standard induction/maintenance protocols for lupus nephritis (LN). However, MMF has not been approved for treating LN in any country, resulting in worldwide off-label use of this immunosuppressant. In order to clarify the real-world use of MMF as a treatment for LN in Japan, Japan College of Rheumatology surveyed the use of MMF in daily clinical practice.Adult patients with LN who visited enrolled hospitals from October 2008 to September 2013 were surveyed for the initial, maximum, and maintenance doses of MMF. The safety and efficacy of MMF were retrospectively evaluated.One hundred and thirty-seven LN patients including 116 females were enrolled. The median of initial, maximum, and maintenance doses of MMF were 1.0 g/day, 1.5 g/day, and 1.0 g/day, respectively. Sixty-one adverse events were reported in 39 patients during the follow-up period. Median urine protein level decreased from 1.89 g/gCr to 0.21 g/gCr, meanC3 level increased from 66.4 mg/dl to 80.3 mg/dl, and median anti-DNA antibody titer decreased from 40.6 IU/ml to 10.6 IU/ml.MMF was commonly used for the treatment of adult LN patients with acceptable efficacy and safety in Japan.Keywords
This publication has 16 references indexed in Scilit:
- Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus NephritisNew England Journal of Medicine, 2011
- Short-term Outcomes of Induction Therapy With Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical TrialAmerican Journal of Kidney Diseases, 2011
- Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS studyRheumatology, 2009
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus NephritisNew England Journal of Medicine, 2005
- Sequential Therapies for Proliferative Lupus NephritisNew England Journal of Medicine, 2004
- Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trialsAmerican Journal of Kidney Diseases, 2004
- Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2002
- Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamideArthritis & Rheumatism, 2002
- Therapy of Lupus NephritisNew England Journal of Medicine, 1986
- Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and CyclophosphamideNew England Journal of Medicine, 1978